The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-29

Study Completion Date

2022-12-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic heart failure (CHF) is one of the major causes of death in Western societies. Evidence has accumulated that functionally active autoantibodies directed against the beta1 adrenergic receptor (β1 AAb) are of pathophysiological relevance for the development and progression of cardiomyopathy and associated CHF. BC 007 is under development for targeted neutralisation of autoantibodies directed against G protein coupled receptors, including β1 AAb. This is an open label, three-centre, randomised phase 2a study in participants with chronic HFrEF. The study will evaluate whether BC 007 causes a persistent neutralisation of the β1 AAb demonstrated by a negative β1 AAb status up to 12 months. Participants will be randomised in a 2:1 ratio to the treatment arm (BC 007) or the control arm (untreated). Treatment is repeated once up to month 11 if the participant's β1 AAb were not neutralised after 1st dosing on day 1 or reoccur.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects

NCT02955420

Healthy Volunteers

COMPLETED PHASE1

Pericarditis: Auto-Inflammation in Recurrent Disease

NCT04996108

Idiopathic Recurrent Pericarditis

UNKNOWN

Pilot Study of COR-1 in Heart Failure

NCT01391507

Cardiomyopathy, Dilated

COMPLETED PHASE2

Effect of Short-term Prednisone Therapy on C-reactive Protein in Patients With Acute Heart Failure

NCT05916586

Acute Heart Failure

COMPLETED NA

Effect of Carvedilol Rapid Up-Titration in Patients With Heart Failure With Reduced Ejection Fraction

NCT05179070

Heart Failure With Reduced Ejection Fraction HFrEF

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective is:

\- To compare the efficacy of an intravenous (i.v.) infusion of BC 007 with an untreated control arm in removal of β1 AAb at month 12 in participants with chronic heart failure with reduced ejection fraction (HFrEF)

Secondary objectives are:

* To evaluate the time to recurrence of β1 AAb after a single i.v. infusion of BC 007
* To evaluate the response rate and time to recurrence of β1 AAb after a repeated single i.v. infusion of BC 007 after the first recurrence of β1 AAb
* To evaluate the safety and tolerability of BC 007 after a single and a repeated single i.v. infusion
* To determine the pharmacokinetic (PK) plasma and urine profiles of BC 007
* To investigate the PK plasma profiles of BC 007 metabolites
* To investigate the β aminoisobutyric acid (β-AIBA) plasma and urine, and uric acid serum and urine concentration as a marker for BC 007 degradation
* To investigate the spontaneous conversion of β1 AAb status from positive to negative in untreated participants (control arm)

Exploratory objective is:

\- To evaluate the change of the left ventricular ejection fraction (LVEF) after a single and a repeated single i.v. infusion

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiomyopathy, Dilated Heart Failure Autoantibodies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BC 007

The treatment arm will comprise 20 randomly allocated β1-AAb positive dilative cardiomyopathy (DCM) patients. Participants will receive a continuous 75 minute infusion of 1350 mg BC 007 at day 1. The β1-AAb status will be monitored 10 days after treatment and every month. Treatment is repeated once up to month 11 if the participant's β1-AAbs were not neutralized after 1st dosing on day 1 or reoccur.

Group Type ACTIVE_COMPARATOR

BC 007

Intervention Type DRUG

1350 mg of BC 007

Control

The control arm will comprise 10 randomly allocated β1-AAb positive DCM patients. Participants will receive standard therapy but no intervention. The β1- AAb status will be monitored every month.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BC 007

1350 mg of BC 007

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participant ≥18 years of age, at the time of signing the informed consent.
* Participant has CHF class II III, according to the NYHA classification.
* Participant has a chronic HFrEF with a left ventricular ejection fraction (LVEF) ≤40 % during screening (as assessed by in-hospital echocardiography).
* Participant screened positive for β1 AAb by a validated functional assay.

Exclusion Criteria

* Participant has a sustained systolic blood pressure ≥160 mmHg prior to randomisation.
* Participant has a sustained bradycardia with resting heart rate \<45 beats per minute (bpm) or tachycardia with resting heart rate \>100 bpm prior to randomisation.
* Participant has an untreated primary valvular disease, considered clinically significant by the Investigator.
* Participant has any condition or therapy, which would make the participant unsuitable for the study, or life expectancy less than 12 months (e.g., active malignancy).

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No